Additionally, to investigate whether PSMD14 inhibitor OPA impairs the malignant biological behaviors of ovarian cancer cells by preventing the ability of PSMD14 to modulate PKM2, we then applied OPA in ovarian cancer cells after downregulation of PKM2 expression. Here, PKM is linked to ovarian carcinoma.